Thermo Fisher Scientific ATX2/SCA2 Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 1:1,000–1:5,000

Immunoprecipitation (IP)

• Tested Dilution: 2–5 µg/mg lysate

Product Specifications

Product Specific Information

• Recommended shelf life: 1 year from date of receipt.

Target Information

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem, and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I–III.
Defects in this gene are the cause of spinocerebellar ataxia type 2 (SCA2). SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I), characterized by cerebellar ataxia in combination with additional clinical features such as optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy, and dementia.
SCA2 is caused by expansion of a CAG repeat in the coding region of this gene. Longer expansions result in earlier onset of the disease. Alternatively spliced transcript variants encoding different isoforms have been identified, but their full-length sequence has not been determined.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.